Home › Upcoming votes › MANGOCEUTICALS, INC.
No fund votes on record from prior seasons.
Read the proxy statement on EDGAR
Summary, checked against the proxy statement. Each point is backed by a passage of the filing, shown under the point; figures under “Last year’s votes” come from the company’s Form 8-K. Read the proxy statement before relying on it.
Combined 2025 and 2026 annual meeting: four directors, a reverse stock split, an equity plan amendment, auditor ratification and an adjournment proposal.
“We did not hold an annual meeting last year and as such we are holding a combined 2025/2026 annual meeting this year.” Find it in the filing
“to effect a reverse stock split of our issued and outstanding shares of our common stock, par value $0.0001 per share, by a ratio of between one-for-two to one-for-twenty-five inclusive, with the exact ratio to be set at a whole number to be determined by our Board of Directors” Find it in the filing
“the primary purpose of the Reverse Stock Split is to increase our stock price in order to regain and maintain compliance with the Nasdaq minimum bid price listing standard” Find it in the filing
“Our Certificate of Formation presently authorizes 200,000,000 shares of common stock and 10,000,000 shares of blank check preferred stock, of which no shares are designated.” Find it in the filing
“the initial aggregate number of shares of common stock that may be issued pursuant to awards under the 2022 Plan shall equal 15,000,000 initially (compared to 11,588,880 currently, as a result of prior automatic increases), and shall be subject to a one-time adjustment to 10,000,000 shares” Find it in the filing
“The Amendment will also provide for automatic annual increases beginning April 1, 2027 and continuing through April 1, 2032, each equal to the lesser of (i) 10% of our outstanding shares of common stock as of the last day of the immediately preceding fiscal year and (ii) 2,000,000 shares” Find it in the filing
“assuming the maximum Reverse Stock Split ratio that may be approved by the Board of Directors, the initial shares available under the 2022 Plan immediately following the Reverse Stock Split would total 250,000,000 shares of common stock” Find it in the filing
“of Turner, Stone & Company, L.L.P., an independent registered public accounting firm, as the Company's independent auditors for the fiscal years ending December 31, 2025 and 2026.” Find it in the filing
“We did not hold an annual meeting last year and as such we are holding a combined 2025/2026 annual meeting this year.” Find it in the filing
Ballot read from the proxy statement and checked. As listed in MANGOCEUTICALS, INC.’s proxy statement, with the board’s recommendation on each item.
| # | Item | Proposed by | Board recommends |
|---|---|---|---|
| 1 | Election of four directors Director election |
Board | For |
| 2 | Amendment to Certificate of Formation to effect a reverse stock split (1-for-2 to 1-for-25) | Board | For |
| 3 | Adoption of the Third Amendment to the 2022 Equity Incentive Plan | Board | For |
| 4 | Ratification of Turner, Stone & Company, L.L.P. as independent auditors for fiscal 2025 and 2026 Auditor |
Board | For |
| 5 | Adjournment of the Annual Meeting, if necessary Adjournment |
Board | For |
The meeting facts and ballot come from the SEC proxy filings listed above. Ballots are read from the proxy statement and checked against the filing’s own text; when that check does not pass, the page shows “see the proxy statement” instead of a ballot. Last year’s figures are the company’s official Form 8-K results and the managers’ Form N-PX reports. Nothing on this page predicts how any shareholder will vote, and it is not investment advice. How this works.